Trial Profile
Multicenter phase II study of Taxotere (docetaxel) administered weekly or every three weeks in combination with prednisone as second line chemotherapy in patients with hormone refractory prostate cancer (HRPC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 12 Jan 2007 Status change
- 12 Sep 2006 New trial record.